May 2023 FDA Recall Bupropion Hydrochloride by Sun Pharmaceutical Industries Inc
D-0761-2023 - Failed Dissolution Specifications; during stability testing

This Class II drug recall was voluntarily initiated by Sun Pharmaceutical Industries Inc on May 9, 2023 for the product Bupropion Hydrochloride. The FDA reported the reason for recall as failed dissolution specifications; during stability testing. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0761-2023

Reason for Recall
Failed Dissolution Specifications; during stability testing
Initiated
05-09-2023
Reported
05-31-2023
Quantity
5,344 Bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
SUN PHARMACEUTICAL INDUSTRIES INC
Nationwide in the U.S.A
buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86

Batch or Lot Expiration Information

Lot# Lots: HAC2240A, Exp 05/2023; HAC3162A, Exp 07/2023